Haleon Plc is experiencing mixed signals in the market, from slumps to minor recoveries.
Barclays upgraded their rating of the stock due to improving US outlook, but later downgraded it due to growth concerns. Despite recent weakness, experts, including
Jim Cramer and
Argus, view the situation as a potential buying opportunity.
Goldman Sachs also upgraded Haleon stock to Buy, forecasting expected growth acceleration. In the lead up to
Feb. 25 results, investors seem to be cautious, causing minor slips in the stock price. Haleon's fundamentals and intrinsic value are seen as strong, despite apparent market misgivings, and it seems set to pay a dividend.
Berenberg and
Morgan Stanley maintain a buy rating despite downward revisions of price targets. Positive changes within the company include board and committee modifications and key managerial share transactions. Haleon's ‘soft’ US demand in 2025 is offset by innovation and potential expansions, portraying an optimistic long-term picture. The company's tie ups with
Salesforce Life Sciences Cloud &
Agentforce and
Altibbi demonstrates their commitment to improving pharmacy and HCP engagement and delivering Arabic oral health support. Despite undervaluation and a cut to organic revenue guidance, Haleon's market outlook brightens amidst favorable trends.
Haleon Stocks News Analytics from Wed, 19 Mar 2025 07:00:00 GMT to Fri, 06 Feb 2026 09:28:00 GMT -
Rating -1
- Innovation 3
- Information 4
- Rumor 1
